Kami J. Maddocks, MD

Kami J. Maddocks, MD, is a hematologist at The Ohio State University Comprehensive Cancer Center—James

Articles

Mantle Cell Lymphoma: Evolving Strategies in Diagnosis & Treatment

June 11th 2025

Kami J. Maddocks, MD; and Morgane Cheminant, MD, PhD, discuss evolving strategies in the diagnosis and treatment of mantle cell lymphoma.

Future Directions in the Treatment of Mantle Cell Lymphoma

August 3rd 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.

Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

July 28th 2023

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

July 28th 2023

Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

July 20th 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma

July 20th 2023

Experts explain the role of maintenance therapy in mantle cell lymphoma and how it impacts the risk of disease progression.

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

May 31st 2023

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

Overview of Mantle Cell Lymphoma

May 31st 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.

Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL

August 3rd 2022

Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.

Concluding Thoughts on the DLBCL Treatment Landscape

February 24th 2022

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Monoclonal Antibodies for Treatment of R/R DLBCL

February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Real-World Data With CAR-T Therapies in R/R DLBCL

February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Safety With CAR-T Therapies in R/R DLBCL

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

CAR-T Therapies in R/R DLBCL

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

CAR-T Therapy

February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.

Front-Line Treatment of DLBCL

January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.